We are live on ! Find out more
CYAD

Celyad Oncology SA American Depositary Shares

Delisted

CYAD was delisted on the 18th of May, 2023.

8 hedge funds and large institutions have $3.24M invested in Celyad Oncology SA American Depositary Shares in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 88 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

64% less capital invested

Capital invested by funds: $9.07M → $3.24M (-$5.83M)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Holders
8
Holders Change
Holders Change %
0%
% of All Funds
0.13%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
2
Increased
1
Reduced
3
Closed
2
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
FIG
1
Fortress Investment Group
New York
$3.2M
Citadel Advisors
2
Citadel Advisors
Florida
$14K +$13.3K +13,165 +79%
Morgan Stanley
3
Morgan Stanley
New York
$9.02K -$608 -600 -3%
OMC
4
Old Mission Capital
Illinois
$8.04K +$16.5K +16,319 New
Millennium Management
5
Millennium Management
New York
$5K +$11.1K +10,993 New
UBS Group
6
UBS Group
Switzerland
$2.84K -$2.96K -2,919 -34%
National Bank of Canada
7
National Bank of Canada
Quebec, Canada
$1.67K
Wells Fargo
8
Wells Fargo
California
$281 -$12.5K -12,300 -96%
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
-$16K -11,602 Closed
Osaic Holdings
10
Osaic Holdings
Arizona
-$2K -1,500 Closed

CYAD Hedge Fund Activity: Q4 2022 in Review

8 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q4 2022, worth a combined $3.24M — down 64% from $9.07M a quarter earlier.

Fund positioning in CYAD was balanced in Q4 2022: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 3 trimmed.

The largest buyer was Old Mission Capital, opening a new position worth an estimated $16.5K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $16K sold.

  • 8 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q4 2022, unchanged from Q3 2022.
  • Funds reported $3.24M of Celyad Oncology SA American Depositary Shares stock for Q4 2022, down 64% quarter-over-quarter.
  • 2 funds opened new Celyad Oncology SA American Depositary Shares positions in Q4 2022 and 2 closed out, a net change of 0 holders.
  • The largest Celyad Oncology SA American Depositary Shares buyer in Q4 2022 was Old Mission Capital, an estimated $16.5K added.
  • The largest Celyad Oncology SA American Depositary Shares seller in Q4 2022 was Susquehanna International Group, an estimated $16K sold.

Based on aggregated 13F filings for Q4 2022.